Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly

Abstract

The metabolic side effects of atypical antipsychotics (AAPs) have been widely studied in younger populations, but research investigating these sequelae in the elderly is lacking. This article reviews the available literature examining the use of AAPs in the elderly, evaluating their association with weight gain and changes in blood glucose and lipid parameters. We find a relative paucity of studies in this area; while some data highlight significant, collective changes in metabolic parameters, the majority suggests an apparent low vulnerability to these side effects. We conclude that the risk and clinical implications of unfavorable metabolic changes in the elderly being treated with AAP medications remain largely undetermined, and we caution against drawing firm conclusions based on the available data. The conflicting evidence leaves us recommending that metabolic monitoring be implemented, with regular follow-up as advocated in other populations.

Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein‐Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study

“…Interestingly, AAP administration exhibited higher ORs of high CVD risk in the patients with low glucose level. In fact, hyperglycaemia and insulin resistance are the other side effects of long‐term AAP use . Some studies have offered generally consistent evidence that treatment of clozapine and olanzapine is associated with an increased risk of diabetes mellitus.…”

Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta‐analysis

“…Antipsychotics (APs) are medications used to treat a wide variety of mental disorders. Despite their name, APs are now indicated for nonpsychotic spectrum illnesses (e.g., autism, treatment refractory depression, bipolar disorder, and Tourette's), with growing prescriptions for off‐label including geriatric and pediatric populations (Carton et al, ; Guenette, Chintoh, Remington, & Hahn, ). APs have gone through many changes resulting in several “generations” of the medications, defined in part according to accompanying adverse effects.…”

Atypical antipsychotics and effects on feeding: from mice to men

“…These observations, combined with evidence of increasing AAP prescriptions for authorized indications (including bipolar disorder, schizophrenia, Tourette's disorder, and autistic disorder), growing offlabel use (anorexia nervosa, dementia, anxiety), and expanding prescription to the pediatric and elderly populations (Domino and Swartz 2008;Guenette et al 2014;Olfson et al 2006;Verdoux et al 2010), make it imperative that we understand the extent of these metabolic side effects and their underlying mechanisms.…”